TTNP
NSCTitan Pharmaceuticals Inc.
Healthcare•Biotechnology
Watchlist:
Last updated: Friday 4th July 2025
4.40
+0.05 (1.15%)
Prev Close:4.35
Open:4.425
Bid:4.3
Ask:4.75
52 Week Range
3.0314.80
Volume:36,477
Mkt Cap:4 M
46
MarketXLS Rank ®
Hold
Price Target
$5.06
+15.0%
Financials
Financial Statements
TTNP - Cash Flow (Annual)
| Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 | Dec-15 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure Reported | 2000.0 | 23000.0 | 540000.0 | 256000.0 | 416000.0 | 175000.0 | 171000.0 | 133000.0 | ||
| Cash Flow From Continuing Investing Activities | 732000.0 | -23000.0 | -540000.0 | -256000.0 | -416000.0 | -175000.0 | -171000.0 | -133000.0 | ||
| Change In Account Payable | -380000.0 | -899000.0 | 50000.0 | -1 M | 901000.0 | -95000.0 | 985000.0 | -3 M | 4000.0 | -138000.0 |
| Change In Payables And Accrued Expense | -380000.0 | -899000.0 | 50000.0 | -1 M | 901000.0 | -95000.0 | 985000.0 | -3 M | 4000.0 | -138000.0 |
| Change In Prepaid Assets | 169000.0 | 177000.0 | 164000.0 | 163000.0 | 391000.0 | -547000.0 | -185000.0 | -125000.0 | -63000.0 | -29000.0 |
| Change In Working Capital | 823000.0 | -916000.0 | 378000.0 | -219000.0 | 2 M | 111000.0 | -542000.0 | 4000.0 | 567000.0 | -2 M |
| Changes In Account Receivables | 46000.0 | -10000.0 | 76000.0 | 772000.0 | 186000.0 | 744000.0 | -2 M | 4 M | 626000.0 | -245000.0 |
| Depreciation And Amortization | 5000.0 | 137000.0 | 196000.0 | 257000.0 | 292000.0 | 244000.0 | 380000.0 | 417000.0 | 377000.0 | 358000.0 |
| Financing Cash Flow | -62000.0 | 10 M | 5 M | 9 M | 18 M | 11 M | 11 M | 7 M | 27000.0 | -14000.0 |
| Gain Loss On Investment Securities | -134000.0 | |||||||||
| Gain Loss On Sale Of PPE | -2 M | |||||||||
| Interest Paid Supplemental Data | 13000.0 | 295000.0 | 432000.0 | 471000.0 | 298000.0 | |||||
| Issuance Of Debt | -62000.0 | 500000.0 | -946000.0 | -2 M | 7 M | |||||
| Net Issuance Payments Of Debt | -62000.0 | 500000.0 | -946000.0 | -2 M | 7 M | |||||
| Net Long Term Debt Issuance | -62000.0 | -946000.0 | -2 M | 7 M | ||||||
| Net PPE Purchase And Sale | 732000.0 | -23000.0 | -540000.0 | -256000.0 | -416000.0 | -175000.0 | -171000.0 | -133000.0 | ||
| Net Preferred Stock Issuance | 10 M | 10 M | ||||||||
| Other Non-cash Items | 1 M | 997000.0 | 2 M | -1 M | 884000.0 | 2 M | 2 M | 1 M | 1 M | |
| Preferred Stock Issuance | 10 M | 10 M | ||||||||
| Proceeds From Issuance Of Warrants | 4000.0 | 7 M | 2 M | 3 M | ||||||
| Proceeds From Stock Option Exercised | 27000.0 | |||||||||
| Purchase Of PPE | -2000.0 | -23000.0 | -540000.0 | -256000.0 | -416000.0 | -175000.0 | -171000.0 | -133000.0 | ||
| Repayment Of Debt | -62000.0 | -250000.0 | -2 M | -3 M | ||||||
| Sale Of PPE | 734000.0 | |||||||||
| Short Term Debt Issuance | 750000.0 | |||||||||
| Short Term Debt Payments | -250000.0 | |||||||||
| Stock Based Compensation | 1 M | 947000.0 | 2 M | 7000.0 | 572000.0 | 2 M | 2 M | 1 M | 1 M | |
| Unrealized Gain Loss On Investment Securities | 923000.0 | |||||||||
| Amord | 25000.0 | 450000.0 | 36000.0 | |||||||
| Begcash | 6 M | 5 M | 5 M | 10 M | 8 M | 14 M | 8 M | 15 M | ||
| Capex | 732000.0 | -23000.0 | -540000.0 | -256000.0 | -416000.0 | -175000.0 | -171000.0 | -133000.0 | ||
| Cffcf | -62000.0 | 10 M | 5 M | 9 M | 18 M | 11 M | 11 M | 7 M | 27000.0 | -14000.0 |
| Cffinv | 732000.0 | -23000.0 | -540000.0 | -256000.0 | -416000.0 | -175000.0 | -171000.0 | -133000.0 | ||
| Cffoa | -4 M | -7 M | -8 M | -8 M | -17 M | -15 M | -8 M | -13 M | 6 M | -7 M |
| Chgcash | -4 M | 4 M | -3 M | 919000.0 | 190000.0 | -4 M | 2 M | -6 M | 6 M | -8 M |
| Chginv | 1000000.0 | 187000.0 | 35000.0 | 287000.0 | 264000.0 | 31000.0 | ||||
| Chgothca | 99000.0 | 120000.0 | ||||||||
| Chgothcl | -12000.0 | -184000.0 | -99000.0 | 295000.0 | -313000.0 | 313000.0 | -2 M | |||
| Chgothwc | -41000.0 | -134000.0 | ||||||||
| Chgpay | -380000.0 | -899000.0 | 50000.0 | -1 M | 901000.0 | -95000.0 | 985000.0 | -3 M | 4000.0 | -138000.0 |
| Chgrec | 46000.0 | -10000.0 | 76000.0 | 772000.0 | 186000.0 | 744000.0 | -2 M | 4 M | 626000.0 | -245000.0 |
| Depamor | 5000.0 | 112000.0 | 196000.0 | 221000.0 | 292000.0 | 244000.0 | 380000.0 | 417000.0 | 377000.0 | 358000.0 |
| Endcash | -4 M | 4 M | 3 M | 6 M | 5 M | 5 M | 10 M | 8 M | 14 M | 8 M |
| Fcf | -4 M | -6 M | -8 M | -8 M | -18 M | -16 M | -9 M | -13 M | 6 M | -8 M |
| Ltdebtiss | 654000.0 | 650000.0 | 7 M | |||||||
| Ltdebtpay | -62000.0 | -2 M | -3 M | |||||||
| Netinccont | -5 M | -6 M | -10 M | -9 M | -18 M | -16 M | -9 M | -14 M | 5 M | -11 M |
| Netothfin | 5 M | 9 M | 12 M | 10 M | 10 M | -14000.0 | ||||
| Netstdebtiss | 500000.0 | |||||||||
| Opcf | -4 M | -7 M | -8 M | -8 M | -17 M | -15 M | -8 M | -13 M | 6 M | -7 M |
| Opgainloss | -2000.0 | -2 M | 2000.0 | -668000.0 | 65000.0 | -226000.0 | -1 M | -619000.0 | -825000.0 | 5 M |
Call: 1-877-778-8358 
Welcome! I'm Ankur, the founder and CEO of MarketXLS. With more than ten years of experience, I have assisted over 2,500 customers in developing personalized investment research strategies and monitoring systems using Excel.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
I invite you to book a demo with me or my team to save time, enhance your investment research, and streamline your workflows.
Implement "your own" investment strategies in Excel with thousands of MarketXLS functions and templates.
MarketXLS provides all the tools I need for in-depth stock analysis. It's user-friendly and constantly improving. A must-have for serious investors.
I have been using MarketXLS for the last 6+ years and they really enhanced the product every year and now in the journey of bringing in AI...
MarketXLS is a powerful tool for financial modeling. It integrates seamlessly with Excel and provides real-time data.
I have used lots of stock and option information services. This is the only one which gives me what I need inside Excel.